Asselah, J. and Sperlich, C. 2013. Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. Canadian Urological Association Journal. 7, 1-2-S1 (Feb. 2013), S11-S17. DOI:https://doi.org/10.5489/cuaj.274.